News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
758,462 Results
Type
Article (54072)
Company Profile (325)
Press Release (704065)
Multimedia
Podcasts (96)
Webinars (13)
Section
Business (218050)
Career Advice (2877)
Deals (37675)
Drug Delivery (120)
Drug Development (86706)
Employer Resources (185)
FDA (17254)
Job Trends (16126)
News (370621)
Policy (36091)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2909)
Academic (1)
Accelerated approval (5)
Adcomms (27)
Allergies (93)
Alliances (53482)
ALS (99)
Alzheimer's disease (1477)
Antibody-drug conjugate (ADC) (147)
Approvals (17230)
Artificial intelligence (284)
Autoimmune disease (24)
Automation (16)
Bankruptcy (388)
Best Places to Work (12221)
BIOSECURE Act (20)
Biosimilars (116)
Biotechnology (213)
Bladder cancer (82)
Brain cancer (30)
Breast cancer (295)
Cancer (2374)
Cardiovascular disease (196)
Career advice (2415)
Career pathing (34)
CAR-T (163)
Cell therapy (455)
Cervical cancer (21)
Clinical research (70260)
Collaboration (889)
Compensation (530)
Complete response letters (28)
COVID-19 (2802)
CRISPR (47)
C-suite (258)
Cystic fibrosis (104)
Data (2235)
Decentralized trials (2)
Denatured (30)
Depression (51)
Diabetes (285)
Diagnostics (6731)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (130)
Drug pricing (120)
Drug shortages (30)
Duchenne muscular dystrophy (100)
Earnings (89579)
Editorial (43)
Employer branding (23)
Employer resources (158)
Events (120210)
Executive appointments (762)
FDA (18537)
Featured Employer (52)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (782)
Gene editing (116)
Generative AI (24)
Gene therapy (338)
GLP-1 (811)
Government (4892)
Grass and pollen (6)
Guidances (54)
Healthcare (20127)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (138)
Indications (30)
Infectious disease (2956)
Inflammatory bowel disease (151)
Inflation Reduction Act (9)
Influenza (54)
Intellectual property (99)
Interviews (554)
IPO (17106)
IRA (49)
Job creations (4339)
Job search strategy (1994)
Kidney cancer (11)
Labor market (38)
Layoffs (526)
Leadership (23)
Legal (8971)
Liver cancer (81)
Lung cancer (341)
Lymphoma (155)
Machine learning (7)
Management (63)
Manufacturing (326)
MASH (73)
Medical device (14028)
Medtech (14033)
Mergers & acquisitions (21106)
Metabolic disorders (748)
Multiple sclerosis (85)
NASH (23)
Neurodegenerative disease (110)
Neuropsychiatric disorders (33)
Neuroscience (2065)
NextGen: Class of 2025 (7156)
Non-profit (4895)
Northern California (2695)
Now hiring (39)
Obesity (402)
Opinion (259)
Ovarian cancer (77)
Pain (94)
Pancreatic cancer (86)
Parkinson's disease (158)
Partnered (21)
Patents (243)
Patient recruitment (111)
Peanut (51)
People (62523)
Pharmaceutical (93)
Pharmacy benefit managers (19)
Phase I (21780)
Phase II (30782)
Phase III (23103)
Pipeline (1211)
Policy (160)
Postmarket research (2969)
Preclinical (9356)
Press Release (71)
Prostate cancer (111)
Psychedelics (38)
Radiopharmaceuticals (258)
Rare diseases (419)
Real estate (6581)
Recruiting (72)
Regulatory (24478)
Reports (47)
Research institute (2576)
Resumes & cover letters (454)
Rett syndrome (5)
RNA editing (5)
RSV (46)
Schizophrenia (78)
Series A (137)
Series B (88)
Service/supplier (14)
Sickle cell disease (58)
Southern California (2324)
Special edition (16)
Spinal muscular atrophy (159)
Sponsored (32)
Startups (3921)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (43)
The Weekly (64)
United States (23651)
Vaccines (770)
Venture capitalists (42)
Weight loss (277)
Women's health (36)
Worklife (18)
Date
Today (218)
Last 7 days (932)
Last 30 days (2818)
Last 365 days (34335)
2025 (10948)
2024 (36829)
2023 (41753)
2022 (52985)
2021 (57656)
2020 (56527)
2019 (49811)
2018 (37735)
2017 (34741)
2016 (34708)
2015 (40736)
2014 (34844)
2013 (30216)
2012 (32198)
2011 (32813)
2010 (31018)
Location
Africa (946)
Alabama (54)
Alaska (7)
Arizona (246)
Arkansas (14)
Asia (43909)
Australia (7764)
California (6192)
Canada (2032)
China (548)
Colorado (272)
Connecticut (280)
Delaware (153)
Europe (96266)
Florida (914)
Georgia (208)
Idaho (61)
Illinois (575)
India (28)
Indiana (321)
Iowa (11)
Japan (162)
Kansas (106)
Kentucky (25)
Louisiana (10)
Maine (62)
Maryland (926)
Massachusetts (4690)
Michigan (222)
Minnesota (406)
Mississippi (2)
Missouri (88)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1749)
New Mexico (30)
New York (1762)
North Carolina (1047)
North Dakota (8)
Northern California (2695)
Ohio (205)
Oklahoma (14)
Oregon (40)
Pennsylvania (1392)
Puerto Rico (13)
Rhode Island (35)
South America (1329)
South Carolina (22)
South Dakota (1)
Southern California (2324)
Tennessee (104)
Texas (917)
Utah (186)
Virginia (156)
Washington D.C. (66)
Washington State (577)
West Virginia (3)
Wisconsin (56)
758,462 Results for "rafael pharmaceuticals formerly known as cornerstone pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc.
May 19, 2022
·
3 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 3, 2025
·
5 min read
Press Releases
Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 25, 2025
·
2 min read
Press Releases
Universe Pharmaceuticals INC Announces Share Consolidation
March 20, 2025
·
3 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Business
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’s Scientific Advisory Board.
July 6, 2022
·
3 min read
Drug Development
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.
June 16, 2022
·
3 min read
Drug Development
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism.
June 16, 2022
·
3 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
1 of 75,847
Next
